Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (432) 432
humans (429) 429
life sciences & biomedicine (412) 412
female (243) 243
male (241) 241
hiv infections - drug therapy (206) 206
heterocyclic compounds, 3-ring - therapeutic use (201) 201
adult (196) 196
heterocyclic compounds, 3-ring - adverse effects (192) 192
middle aged (175) 175
heterocyclic compounds, 3-ring - administration & dosage (166) 166
infectious diseases (145) 145
pharmacology & pharmacy (139) 139
heterocyclic compounds, 3-ring - pharmacology (124) 124
treatment outcome (108) 108
aged (90) 90
dolutegravir (89) 89
drug therapy, combination (83) 83
human immunodeficiency virus--hiv (82) 82
hiv (79) 79
animals (78) 78
drug therapy (78) 78
immunology (76) 76
heterocyclic compounds, 3-ring - pharmacokinetics (75) 75
hiv integrase inhibitors - adverse effects (70) 70
hiv integrase inhibitors - therapeutic use (70) 70
young adult (69) 69
clinical trials (64) 64
simeprevir (63) 63
abridged index medicus (61) 61
hiv infections - virology (60) 60
antiretroviral drugs (59) 59
antiviral agents (59) 59
hiv-1 - drug effects (58) 58
anti-hiv agents - therapeutic use (56) 56
aids/hiv (54) 54
analysis (54) 54
biological and medical sciences (53) 53
anti-hiv agents - adverse effects (49) 49
drug interactions (49) 49
hiv infection (49) 49
hiv integrase inhibitors - administration & dosage (49) 49
medical sciences (49) 49
sulfonamides - therapeutic use (49) 49
adolescent (48) 48
anti-hiv agents - administration & dosage (48) 48
antiviral agents - therapeutic use (47) 47
virology (46) 46
care and treatment (45) 45
health aspects (44) 44
microbiology (44) 44
oncology (44) 44
hepatitis c, chronic - drug therapy (43) 43
patients (43) 43
research (42) 42
mice (41) 41
antiretroviral therapy (38) 38
drug combinations (38) 38
hiv integrase inhibitors - pharmacokinetics (38) 38
double-blind method (37) 37
drug administration schedule (37) 37
viral load (37) 37
general & internal medicine (36) 36
medicine, general & internal (36) 36
dose-response relationship, drug (35) 35
drug resistance, viral (35) 35
hepacivirus - genetics (35) 35
sulfonamides - adverse effects (35) 35
pharmacokinetics (34) 34
mutation (33) 33
hiv-1 (32) 32
gastroenterology & hepatology (31) 31
pharmacology. drug treatments (31) 31
research article (31) 31
clinical trials as topic (30) 30
dosage and administration (30) 30
hepatitis c virus (30) 30
ribavirin - therapeutic use (30) 30
studies (30) 30
uridine monophosphate - analogs & derivatives (30) 30
viral load - drug effects (30) 30
genotype (29) 29
integrase (29) 29
sofosbuvir (29) 29
hepatitis c (28) 28
proto-oncogene proteins c-akt - antagonists & inhibitors (28) 28
retrospective studies (28) 28
cd4 lymphocyte count (27) 27
pharmacology (27) 27
rna, viral - blood (27) 27
acquired immune deficiency syndrome--aids (26) 26
drug resistance (26) 26
hepacivirus - drug effects (26) 26
hiv integrase inhibitors - pharmacology (26) 26
infections (26) 26
medical research (26) 26
randomized controlled trials as topic (26) 26
safety (26) 26
highly active antiretroviral therapy (25) 25
hiv-1 - genetics (25) 25
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (470) 470
Russian (4) 4
German (3) 3
French (2) 2
Spanish (2) 2
Hungarian (1) 1
Japanese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
by Genovese, Mark C and Fleischmann, Roy and Combe, Bernard and Hall, Stephen and Rubbert-Roth, Andrea and Zhang, Ying and Zhou, Yijie and Mohamed, Mohamed-Eslam F and Meerwein, Sebastian and Pangan, Aileen L
The Lancet (British edition), ISSN 0140-6736, 06/2018, Volume 391, Issue 10139, pp. 2513 - 2524
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Severity of Illness Index | Double-Blind Method | Antirheumatic Agents - administration & dosage | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Middle Aged | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Janus Kinase Inhibitors - adverse effects | Janus Kinase Inhibitors - pharmacology | Janus Kinase Inhibitors - administration & dosage | Arthritis, Rheumatoid - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Methotrexate - administration & dosage | Aged | Rheumatoid factor | Care and treatment | Antirheumatic agents | Analysis | Clinical trials | Product development | Arthritis | Pharmaceutical industry | Drugs | C-reactive protein | Rhinopharyngitis | Infections | Urinary tract | Kinases | Evidence-based medicine | Skin cancer | Proteins | Respiratory tract | Randomization | Motivation | Janus kinase | Respiratory tract diseases | Tumor necrosis factor-TNF | Safety | Herpes zoster | Effectiveness | Medical treatment | Rheumatology | Disease control | Patients | Embolism | Studies | Intolerance | Rheumatoid arthritis | TNF inhibitors | Health risk assessment | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Adverse events of raltegravir and dolutegravir
by Elzi, Luigia and Erb, Stefan and Furrer, Hansjakob and Cavassini, Matthias and Calmy, Alexandra and Vernazza, Pietro and Günthard, Huldrych and Bernasconi, Enos and Battegay, Manuel and Swiss HIV Cohort Study Group
AIDS (London), 08/2017, Volume 31, Issue 13, p. 1853
Raltegravir Potassium - adverse effects | Mental Disorders - epidemiology | Prospective Studies | Mental Disorders - chemically induced | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Male | Withholding Treatment | Switzerland | Drug-Related Side Effects and Adverse Reactions - epidemiology | Anti-HIV Agents - administration & dosage | Young Adult | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Aged, 80 and over | Adult | Female | HIV Infections - drug therapy | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
by Burmester, Gerd R and Kremer, Joel M and Van den Bosch, Filip and Kivitz, Alan and Bessette, Louis and Li, Yihan and Zhou, Yijie and Othman, Ahmed A and Pangan, Aileen L and Camp, Heidi S
The Lancet (British edition), ISSN 0140-6736, 06/2018, Volume 391, Issue 10139, pp. 2503 - 2512
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Severity of Illness Index | Double-Blind Method | Antirheumatic Agents - administration & dosage | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Middle Aged | Male | Disease Progression | Janus Kinase Inhibitors - adverse effects | Janus Kinase Inhibitors - pharmacology | Janus Kinase Inhibitors - administration & dosage | Arthritis, Rheumatoid - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adult | Female | Methotrexate - administration & dosage | Aged | Rheumatoid factor | Care and treatment | Antirheumatic agents | Analysis | Clinical trials | Arthritis | Product development | Drugs | Headache | C-reactive protein | Viruses | Rhinopharyngitis | Infections | Leflunomide | Evidence-based medicine | Regulatory approval | Skin cancer | Proteins | Respiratory tract | Randomization | Varicella | Rheumatism | Janus kinase | Respiratory tract diseases | Sulfasalazine | Tumor necrosis factor-TNF | Methotrexate | Drug dosages | Signs and symptoms | Herpes zoster | Effectiveness | Rheumatology | Melanoma | Nausea | Disease control | Patients | Studies | Rheumatoid arthritis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
by Timothy A. Yap and Li Yan and Amita Patnaik and Ivy Fearen and David Olmos and Kyriakos Papadopoulos and Richard D. Baird and Liliana Delgado and Adekemi Taylor and Lisa Lupinacci and Ruth Riisnaes and Lorna L. Pope and Simon P. Heaton and George Thomas and Michelle D. Garrett and Daniel M. Sullivan and Johann S. de Bono and Anthony W. Tolcher
Journal of clinical oncology, ISSN 0732-183X, 12/2011, Volume 29, Issue 35, pp. 4688 - 4695
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Humans | Middle Aged | Neoplasms - enzymology | Male | Protein Kinase Inhibitors - adverse effects | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Aged, 80 and over | Adult | Female | Aged | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Neoplasms - pathology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
by Mohamed, Mohamed-Eslam F and Camp, Heidi S and Jiang, Ping and Padley, Robert J and Asatryan, Armen and Othman, Ahmed A
Clinical pharmacokinetics, ISSN 0312-5963, 12/2016, Volume 55, Issue 12, pp. 1547 - 1558
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Drug Administration Schedule | Administration, Oral | Antirheumatic Agents - administration & dosage | Area Under Curve | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Janus Kinase 1 - antagonists & inhibitors | Young Adult | Arthritis, Rheumatoid - drug therapy | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Adolescent | Antirheumatic Agents - adverse effects | Adult | Antirheumatic Agents - pharmacokinetics | Female | Aged | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Antirheumatic Agents - therapeutic use
Journal Article
Details down arrow
6. Full Text Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers
by Yap, Timothy A and Yan, Li and Patnaik, Amita and Tunariu, Nina and Biondo, Andrea and Fearen, Ivy and Papadopoulos, Kyriakos P and Olmos, David and Baird, Richard and Delgado, Liliana and Tetteh, Ernestina and Beckman, Robert A and Lupinacci, Lisa and Riisnaes, Ruth and Decordova, Shaun and Heaton, Simon P and Swales, Karen and DeSouza, Nandita M and Leach, Martin O and Garrett, Michelle D and Sullivan, Daniel M and De Bono, Johann S and Tolcher, Anthony W
Clinical cancer research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5672 - 5685
Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Neoplasms - diagnosis | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Biomarkers - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Treatment Outcome | Neoplasms - drug therapy | Diagnostic Imaging | Magnetic Resonance Imaging | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Protein Kinase Inhibitors - therapeutic use | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Aged | Drug Monitoring | Neoplasm Staging | Neoplasms - pathology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
by Min, Sherene and Sloan, Louis and Dejesus, Edwin and Hawkins, Trevor and McCurdy, Lewis and Song, Ivy and Stroder, Richard and Chen, Shuguang and Underwood, Mark and Fujiwara, Tamio and Piscitelli, Stephen and Lalezari, Jay
AIDS (London), ISSN 0269-9370, 09/2011, Volume 25, Issue 14, pp. 1737 - 1745
pharmacokinetics | dose response | antiretroviral therapy | pharmacodynamics | integrase inhibitor | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Anti-HIV Agents - pharmacology | Double-Blind Method | Drug Administration Schedule | Area Under Curve | HIV-1 - drug effects | Heterocyclic Compounds, 3-Ring - pharmacology | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Dose-Response Relationship, Drug | Anti-HIV Agents - pharmacokinetics | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
by Joseph J. Eron and Bonaventura Clotet and Jacques Durant and Christine Katlama and Princy Kumar and Adriano Lazzarin and Isabelle Poizot-Martin and Gary Richmond and Vincent Soriano and Mounir Ait-Khaled and Tamio Fujiwara and Jenny Huang and Sherene Min and Cindy Vavro and Jane Yeo and VIKING Study Grp and VIKING Study Group and for the VIKING Study Group
The Journal of infectious diseases, ISSN 0022-1899, 3/2013, Volume 207, Issue 5, pp. 740 - 748
MAJOR ARTICLES AND BRIEF REPORTS | S/GSK1349572 | DTG | integrase inhibitor | Dolutegravir | raltegravir resistance | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Miscellaneous | Infectious diseases | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Virology | Anti-HIV Agents - pharmacology | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | RNA, Viral - blood | Viral Load | Anti-HIV Agents - administration & dosage | Young Adult | HIV-1 - isolation & purification | Pyrrolidinones - pharmacology | Adult | Female | Antiretroviral Therapy, Highly Active - methods | Raltegravir Potassium | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Treatment Outcome | Plasma - virology | Pilot Projects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | HIV Infections - drug therapy | Aged | Index Medicus | Abridged Index Medicus | Major and Brief Reports | GSK1349572
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study
by Fried, Michael W and Buti, Maria and Dore, Gregory J and Flisiak, Robert and Ferenci, Peter and Jacobson, Ira and Marcellin, Patrick and Manns, Michael and Nikitin, Igor and Poordad, Fred and Sherman, Morris and Zeuzem, Stefan and Scott, Jane and Gilles, Leen and Lenz, Oliver and Peeters, Monika and Sekar, Vanitha and Smedt, Goedele and Beumont‐Mauviel, Maria
Hepatology (Baltimore, Md.), ISSN 0270-9139, 12/2013, Volume 58, Issue 6, pp. 1918 - 1929
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Simeprevir | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Ribavirin - administration & dosage | Adult | Female | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Interferon-alpha - adverse effects | Viral Load - drug effects | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
by Clotet, Bonaventura, Dr and Feinberg, Judith, Prof and van Lunzen, Jan, Prof and Khuong-Josses, Marie-Aude, MD and Antinori, Andrea, MD and Dumitru, Irina, MD and Pokrovskiy, Vadim, Prof and Fehr, Jan, MD and Ortiz, Roberto, MD and Saag, Michael, Prof and Harris, Julia, MA and Brennan, Clare, DPT and Fujiwara, Tamio, PhD and Min, Sherene, MD and ING114915 Study Team
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 383, Issue 9936, pp. 2222 - 2231
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | HIV-1 | Darunavir | Drug Administration Schedule | Ritonavir - administration & dosage | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Anti-HIV Agents - administration & dosage | Young Adult | Creatinine - metabolism | Ritonavir - adverse effects | Analysis of Variance | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Adolescent | Sulfonamides - adverse effects | Adult | Female | HIV Infections - drug therapy | Aged | Sulfonamides - administration & dosage | Serum Albumin - metabolism | Dosage and administration | Research | Drug therapy | Comparative analysis | HIV infection | Antiretroviral drugs | Mutation | Drug dosages | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir
by Anderson, Matt S and Khalilieh, Sauzanne and Yee, Ka Lai and Liu, Rachael and Fan, Li and Rizk, Matthew L and Shah, Vedangi and Hussaini, Azra and Song, Ivy and Ross, Lisa L and Butterton, Joan R
Clinical pharmacokinetics, ISSN 0312-5963, 06/2017, Volume 56, Issue 6, pp. 661 - 669
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | HIV Integrase Inhibitors - pharmacology | Triazoles - adverse effects | Triazoles - blood | Reverse Transcriptase Inhibitors - blood | Area Under Curve | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Reverse Transcriptase Inhibitors - pharmacology | Male | Pyridones - blood | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Reverse Transcriptase Inhibitors - pharmacokinetics | Drug Interactions | Adult | Female | Triazoles - pharmacokinetics | Fasting - metabolism | Drug Therapy, Combination | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Pyridones - pharmacokinetics | HIV Integrase Inhibitors - pharmacokinetics | Triazoles - pharmacology | HIV Integrase Inhibitors - adverse effects | Heterocyclic Compounds, 3-Ring - blood | Heterocyclic Compounds, 3-Ring - adverse effects | HIV Integrase Inhibitors - blood | Pyridones - adverse effects | Pyridones - pharmacology
Journal Article
Details down arrow